Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Aqneursaintrabio.com · Low evidenceIntraBio is a biotechnology company focused on discovering and developing novel drugs for rare neurodegenerative diseases with high unmet medical needs. Its lead programs include the IB1000 series and IB1001 for Niemann-Pick disease type C, with a pivotal trial whose positive results were published in the NEJM and an NDA accepted by the FDA for IB1001. The company emphasizes translating research into potential treatments to improve patients' lives through a science-led program, clinical trials, and a robust pipeline.
Parse Score